surmount-1 tirzepatide non-diabetic obesity weight loss for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - SURMOUNT-1
Description
This part is simple
The liquid solution should be clear, colorless (or slightly yellow), and free of particles
however, studying participants who received 75% or more of the assigned doses allowed for some dosing variation without confounding the outcomes for late responders to tirzepatide
00656-2/asset/38c98550-9ec2-44e8-ba6a-dbb815075666/main.assets/gr1_lrg.jpg)
Compounded medications are only indicated for patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product
Method 3: Calculator verification Use the SeekPeptides peptide calculator as a third independent check
